Navigation Links
Exicycler™ Real-time Thermal Block

ProductsExicycler™ Real-time Thermal Block
Company Bioneer
Item Exicycler™ Real-time Thermal Block
Features Inquire
Description Exicycler Real Time Thermal Block and its operation software are optimized for applications such as quantification of gene expression, genotyping, counting bacterial/viral loads, melt-curve analysis, and validation of microarray results. Exicycler is capable of measuring mutual interactions between two molecules, such as protein-protein and protein-ligand, using fluorescence resonance energy transfer (FRET). The sensitivity, accuracy, and system integration-ready design of Exicycler makes it ideal for high-throughput analysis. The optics and illumination system in Exicycler allow for dynamic, sensitive, and linear detection of signals over a dynamic range of sample concentrations.

Not available in U.S.

Info Bioneer
Customer Service: 240.453.8461
Web site: http://eng.bioneer.com/

Related medicine products :

1. CoolGard 3000 Thermal Regulation System
2. iEMS Thermal Holder HT
3. Thermal Seal, Clear
4. ThermalSeal (non-sterile)
5. ThermalSeal RT Optically Clear Adhesive Plate Film (2mil)
6. ThermalSeal RT Optically Clear Adhesive Plate Film (5mil)
7. ThermalSeal (sterile)
8. iCycler Thermal Cycler
9. Gene Cycler Thermal Cycler
10. PCR Sprint Thermal Cycler
11. Px2 Thermal Cycler Chassis
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
Medicine Products:
(Date:12/3/2008)... CHICAGO, Dec. 3 Breast-Specific ...nd better specificity than breast MRI in patients ...ultrasound in the diagnosis of,breast cancer, acc...eeting of,the Radiological Society of North Ameri...hnique used as an adjunctive tool to mammography t...
(Date:12/3/2008)... Those who don,t respond at first not helped by m...DNESDAY, Dec. 3 (HealthDay News) -- Maintenance th...tients with advanced chronic hepatitis C who haven... research suggests. , The study also showed a s...sease over the course of four years. , "This co...
(Date:12/3/2008)... , , A Minimal 2% Growth in the Baccalaur...ve Reached Enrollment Capacity , , WASHIN...an Association of Colleges of Nursing (AACN) today...ollment in entry-level baccalaureate nursing progr...8. Though this marks the eighth consecutive year ...
(Date:12/3/2008)... GEORGIA, Vt., Dec. 3 In response...a in this difficult economy, a nutritional expert,...urging parents to breastfeed,or use formula respo..., "It is critical that parents refrain from ...se tough economic times," said Barbara S. Levine, ...
Breaking Medicine News(10 mins):Health News:Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer 2Health News:Hepatitis C Therapy Useless for Some 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 3Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 4Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 5Health News:Cornell Nutritional Expert, Vermont Baby Formula Company Urge Parents Not to Dilute Formula with Extra Water 2
...y researchers at Washington University School of M... of a protein that absorbs lipids in the upper par...vide a novel approach for obesity treatment in the.... Nada A. Abumrad, the Dr. Robert C. Atkins Profes...
...sis of five major breast cancer trials has confirm...astuzumab and chemotherapy improves survival in w...At the ESMO Conference Lugano, Issa Dahabreh from ...e results of a meta-analysis of 5 trials involving...
...study,the rogue proteins that cause chronic wastin...ir infectious nature when bound to common soil par... Science (PLoS) Pathogens, a group led by Universi...dd Aiken reports that prions, the protein agents o...
...n people in the US could be suffering from atrial ...atients is forecast to soar. It is a condition i... should. Instead of beating in a regular, normal p...rregularly and too fast.The two small upper chambe...
Other Medicine News:Health News:Protein That Absorbs Lipids may Provide Future Weight-loss Strategies 2Health News:Combination of Tratuzumab and Chemotherapy Yields Better Results for Breast Cancer 2Health News:Prions Capacity can Be Aggrevated by Solid Particles 2Health News:Prions Capacity can Be Aggrevated by Solid Particles 3Health News:Clamor for Catheter-based Ablation Increasing Among Heart Patients in US 2Health News:Clamor for Catheter-based Ablation Increasing Among Heart Patients in US 3
(Date:12/2/2008)...re-USNewswire/ -- Researchers using functional,MR... area of the brain,responsible for suppressing me...stress-related psychiatric disorders. Results of t...eting of the Radiological Society of North America...sion and other stress-related disorders,traumati...
(Date:12/2/2008)...ewswire/ -- Horizon Therapeutics, Inc., a,private... that two pivotal,Phase 3 trials evaluating its l...et all primary endpoints. HZT-501, a novel, propri...buprofen and famotidine, demonstrated a,statistic...-steroidal,anti-inflammatory drug (NSAID)-induced...
(Date:12/1/2008)...wire/ -- TargeGen has announced that an oral,pres...er, US-based clinical,trial of TG101348 in myelop...t,the 2008 American Society of Hematology (ASH) M... as follows:, Title: A Phase I ... JAK2-Selective Inhibitor, in Pati...
(Date:12/1/2008)... the best policy , , ROCHESTER, Minn., Dec...yo Clinic finds the use of the drug therapy etaner...an acute inflammation of the liver caused by exces...udy are published in the December issue of Gastro... , VIDEO ALERT: Additional audio and video r...
Breaking Medicine Technology:Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3MIT 3A Safe storage of greenhouse gas carbon dioxide 5901 1MIT 3A Safe storage of greenhouse gas carbon dioxide 5901 2U of U researchers to use patients own stem cells to treat heart failure 29955 1U of U researchers to use patients own stem cells to treat heart failure 29955 2Necessary lattes 3F 29953 1Necessary lattes 3F 29953 2Bottoms up 3A Individualists more likely to be problem drinkers 29951 1Bottoms up 3A Individualists more likely to be problem drinkers 29951 2
...A Pharmaceuticals,Inc. (Nasdaq:ACAD) today announc...izophrenia co-therapy trial with ACP-103, ACADIA,s... The trial,evaluated ACP-103 co-therapy when used ...ribed atypical antipsychotic drug, or,haloperidol,...apy,arms with ACP-103 demonstrated statistically s...
.../ -- La Jolla,Pharmaceutical Company today announc... Phase 3 trial of Riquent(R) (abetimus,sodium), it...("lupus" or "SLE"). The updated analyses reinforce...e and significant dose response,between the 100 mg... placebo (p=0.0001). These interim data were initi...
Other Medicine Technology:Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 2Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 3Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 4Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 5Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 6La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6